Sign in

MDXG on Nasdaq

MIMEDX GROUP, INC.

In its 2026 annual report the company says: “MIMEDX is a pioneer and leader focused on helping humans heal. Today, our product portfolio is routinely used to help clinicians treat patients suffering from chronic and other hard-to-heal wounds, in wound care and in an increasing number of surgical specialties.”4 It is headquartered in Marietta, Georgia.1 Its shares trade on Nasdaq under the symbol MDXG.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with ACCURAY INC, CryoLife or GLAUKOS Corp, or pick any stock.

  • TickerMDXG on Nasdaq1
  • IndustrySurgical & Medical Instruments & Apparatus1
  • HeadquartersMarietta, Georgia1
  • Business address1775 W Oak Commons Court, Ne, Marietta, Ga 300622
  • Filer categoryLarge accelerated filer2

See how the biggest companies compare on our leaderboards

MIMEDX is a pioneer and leader focused on helping humans heal. With nearly two decades of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

82.6%Gross margin5
15.3%Operating margin5
11.6%Net margin5
20.0%Revenue growth, 20255
18.9%Return on equity5
0.06×Debt to equity5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Wound brought in 66% of the revenue MIMEDX GROUP, INC. broke down this way in fiscal 2025.

  1. Wound$276.3M566%up 20% from 2024
  2. Surgical$142.3M534%up 21% from 2024
Products and services by year
Products and services202320242025
Wound$205.7M$231.0M$276.3M
Surgical$115.8M$117.9M$142.3M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue17¢$73.0M
  • Research and development4¢$15.1M
  • Selling, general and admin63¢$266.2M
  • Income tax4¢$17.7M
  • Profit12¢$48.6M

Out of $418.6M in revenue.5

Where each dollar of operating cash went, fiscal 2025

  • Kept or used elsewhere100¢$74.0M

Out of $74.0M of cash from operations.5

Financial statements

Revenue67895$418.6M in 2025+40% since 2019
0$200.0M$400.0M$600.0M2019: $299.3M$299.3M20192020: $248.2M$248.2M2020−17%2021: $242.0M$242.0M2021−3%2022: $267.8M$267.8M2022+11%2023: $321.5M$321.5M2023+20%2024: $348.9M$348.9M2024+9%2025: $418.6M$418.6M2025+20%
Gross profit67895$345.6M in 2025+35% since 2019
0$100.0M$200.0M$300.0M$400.0M2019: $256.2M$256.2M20192020: $208.9M$208.9M2020−18%2021: $202.4M$202.4M2021−3%2022: $219.5M$219.5M2022+8%2023: $266.8M$266.8M2023+22%2024: $288.8M$288.8M2024+8%2025: $345.6M$345.6M2025+20%
Operating income67895$63.9M in 2025
-$50.0M0$50.0M$100.0M2019: -$21.2M-$21.2M20192020: -$45.4M-$45.4M2020+115%2021: -$7.1M-$7.1M2021−84%2022: -$14.7M-$14.7M2022+109%2023: $37.1M$37.1M20232024: $58.9M$58.9M2024+59%2025: $63.9M$63.9M2025+9%
Net income67895$48.6M in 2025
-$50.0M0$50.0M$100.0M2019: -$25.6M-$25.6M20192020: -$49.3M-$49.3M2020+93%2021: -$10.3M-$10.3M2021−79%2022: -$30.2M-$30.2M2022+194%2023: $58.2M$58.2M20232024: $42.4M$42.4M2024−27%2025: $48.6M$48.6M2025+15%

Every line of the income statement as filed: the last 3 fiscal years, latest first.5

Period ending2025-12-312024-12-312023-12-31
Net sales$418.6M$348.9M$321.5M
Cost of sales$73.0M$60.1M$54.6M
Gross profit$345.6M$288.8M$266.8M
Selling, general and administrative$266.2M$225.1M$211.1M
Research and development$15.1M$12.3M$12.7M
Investigation, restatement and related$0-$8.7M$5.2M
Amortization of intangible assets$439.0K$765.0K$762.0K
Impairment of intangible assets$0$446.0K$0
Operating income$63.9M$58.9M$37.1M
Interest income (expense), net$2.9M-$1.0M-$6.5M
Other expense, net-$558.0K-$565.0K-$26.0K
Income from continuing operations before income tax$66.3M$57.3M$30.6M
Income tax provision (expense) benefit from continuing operations-$17.7M-$15.3M$36.8M
Net income from continuing operations$48.6M$42.0M$67.4M
Income (loss) from discontinued operations, net of tax$0$421.0K-$9.2M
Net income$48.6M$42.4M$58.2M
Net income available to common stockholders from continuing operations$48.6M$42.0M$55.8M
Continuing operations - basic (in dollars per share)$0$0$0
Discontinued operations - basic (in dollars per share)$0$0-$0
Basic net income per common share (in dollars per share)$0.33$0.29$0.40
Continuing operations (in dollars per share)$0$0$0
Discontinued operations (in dollars per share)$0$0-$0
Diluted net income (loss) per common share (in dollars per share)$0.32$0.28$0.37
Weighted average shares outstanding - basic (in shares)147.8M shares147.0M shares116.5M shares
Weighted average shares outstanding - diluted (in shares)149.7M shares149.0M shares146.0M shares

Compare MIMEDX GROUP, INC. with another company

Corporate structure

MIMEDX GROUP, INC. sits at the top of its group. 5 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of MIMEDX GROUP, INC.

  • MIMEDX GROUP, INC. Marietta, Georgia
    • MiMedx Japan, Godo Kaisha Subsidiary · Japan
    • MiMedx Processing Services, LLC Subsidiary · Florida, United States
    • MiMedx Supply, LLC Subsidiary · Delaware, United States
    • MiMedx Tissue Services, LLC Subsidiary · Georgia, United States

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What MIMEDX GROUP, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Operating-lease assets (leased space)$4.3M5 Dec 31, 2025$5.6M5 Dec 31, 2024−22.5%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$166.1M5 Dec 31, 2025$104.4M5 Dec 31, 2024+59.1%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$19.4M5 Dec 31, 2025$19.4M5 Dec 31, 20240%
Intangible assets, net (excluding goodwill)$14.2M5 Dec 31, 2025$11.6M5 Dec 31, 2024+21.8%
Finite-lived intangibles, gross$37.3M5 Dec 31, 2025$21.9M5 Dec 31, 2024+70.3%
Accumulated amortization$24.2M5 Dec 31, 2025$11.6M5 Dec 31, 2024+108.9%
Finite-lived intangibles, net$13.1M5 Dec 31, 2025$10.3M5 Dec 31, 2024+27.0%

Inventory

ItemLatestA year beforeChange
Inventory, total$25.3M5 Dec 31, 2025$23.8M5 Dec 31, 2024+6.4%
Raw materials$1.2M5 Dec 31, 2025$1.0M5 Dec 31, 2024+20.9%
Work in process$8.7M5 Dec 31, 2025$8.6M5 Dec 31, 2024+1.0%
Finished goods$15.5M5 Dec 31, 2025$14.2M5 Dec 31, 2024+8.7%

Properties, in its own words

Our corporate headquarters are located in Marietta, Georgia, where we lease office, laboratory, tissue processing and warehouse space. We also lease a facility in Kennesaw, Georgia, which primarily consists of laboratory, tissue processing and warehouse space. Our properties are used for the manufacture of most of the product lines that we sell, as well as office space for operations, quality, and shared service functions. We believe that such properties are suitable and adequate to meet the needs of our business.

Item 2 of the 10-K filed Feb 25, 2026.4

Leadership

Who has led MIMEDX GROUP, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Parker H. Petit2009–2018
  2. Todd Newton2022
  3. Joseph H. Capper2023–now

Chair

  1. Steve Gorlin2008
  2. Parker H. Petit2014–2018

President

  1. Ken Cleon Edwards2007–2008
  2. Rufus Lewis Bennett Sr.2008
  3. Brian J. Splan2008
  4. Parker H. Petit2009
  5. Rohit Kashyap2022

Chief financial officer

  1. John C. Thomas2008
  2. Michael J. Culumber2009
  3. Michael J. Senken2010–2018
  4. Edward Borkowski2018–2019
  5. Peter M. Carlson2020–2023
  6. Rice Doug2023–now

Chief operating officer

  1. Rebeccah Covert Brown2008–2009
  2. Ricci S. Whitlow2023–now
2010201520202025
Board members and other officers (38)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • MiMedx Japan, Godo Kaisha Japan3
  • MiMedx Processing Services, LLC Florida3
  • MiMedx Supply, LLC Delaware3
  • MiMedx Tissue Services, LLC Georgia3

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • Alynx, Co.Mar 6, 2007 to Apr 2, 20082

Timeline

  1. Aug 11, 20268-K Entered a material agreement; Regulation FD disclosure66
  2. Jul 29, 20268-K Entered a material agreement; Regulation FD disclosure67
  3. Jul 29, 20268-K Results of operations; Regulation FD disclosure68
  4. Jun 16, 20268-K Bylaws or fiscal year changed; Shareholder vote69
  5. Apr 29, 20268-K Results of operations; Regulation FD disclosure70
  6. Apr 16, 20268-K Executive or director change; Regulation FD disclosure71
  7. Feb 25, 20268-K Results of operations; Regulation FD disclosure72
  8. Jan 12, 20268-K Regulation FD disclosure73
  9. Oct 29, 20258-K Results of operations; Regulation FD disclosure74
  10. Sep 3, 20258-K Regulation FD disclosure75
  11. Jul 30, 20258-K Results of operations; Regulation FD disclosure76
  12. Jun 20, 20258-K Shareholder vote77
  13. Jan 31, 2023New chief executive Joseph H. Capper becomes CEO13
  14. Sep 19, 2022New chief executive Todd Newton becomes CEO14
  15. Feb 26, 2009New chief executive Parker H. Petit becomes CEO15

Calendar

Coming up

  1. Oct 28, 2026 · After the closeReports results for the quarter ending Sep/2026 A year earlier it reported $0.15 a share, on Oct 29, 2025.78

When it reported results

  1. Jul 29, 2026Reported quarterly or annual results68
  2. Apr 29, 2026Reported quarterly or annual results70
  3. Feb 25, 2026Reported quarterly or annual results72
  4. Oct 29, 2025Reported quarterly or annual results74
  5. Jul 30, 2025Reported quarterly or annual results76
  6. Apr 30, 2025Reported quarterly or annual results79
  7. Feb 26, 2025Reported quarterly or annual results80
  8. Oct 30, 2024Reported quarterly or annual results81

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

310 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 64 major events, 145 insider forms, 16 large holders, 64 other. The latest 20:

  1. Sep 4, 2026EFFECT EDGAR
  2. Sep 4, 2026424B3 PROSPECTUS EDGAR
  3. Aug 25, 2026S-4 REGISTRATION STATEMENT EDGAR
  4. Aug 11, 2026425 EDGAR
  5. Aug 11, 20268-K/A EDGAR
  6. Jul 30, 2026425 EDGAR
  7. Jul 30, 2026425 EDGAR
  8. Jul 29, 2026425 EDGAR
  9. Jul 29, 20268-K EDGAR
  10. Jul 29, 2026425 EDGAR
  11. Jul 29, 202610-Q EDGAR
  12. Jul 29, 20268-K EDGAR
  13. Jul 29, 2026425 EDGAR
  14. Jul 29, 2026425 EDGAR
  15. Jul 7, 20264 EDGAR
  16. Jun 25, 20264 EDGAR
  17. Jun 16, 20268-K EDGAR
  18. Jun 12, 20264 EDGAR
  19. Jun 12, 20264 EDGAR
  20. Jun 12, 20264 EDGAR

The 310 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

62 open-market trades by officers, directors and large owners since October 2021: 4 buys and 58 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 6, 2025Maersk-Moller KimberlyChief Commercial OfficerSale58,300$7.42$432.6KForm 4
May 2, 2025Capper Joseph HChief Executive OfficerBuy200,000$6.34$1.3MForm 4
Mar 17, 2025Maersk-Moller KimberlyChief Commercial OfficerSale1,759$8.04$14.1KForm 4
Mar 13, 2025Hulse William Frank IVGeneral Counsel and CAOSale54,596$7.89$430.8KForm 4
Mar 13, 2025Maersk-Moller KimberlyChief Commercial OfficerSale4,106$7.89$32.4KForm 4
Mar 10, 2025Hulse William Frank IVGeneral Counsel and CAOSale81,446$7.80$635.3KForm 4
Feb 28, 2025Maersk-Moller KimberlyChief Commercial OfficerSale2,111$8.41$17.8KForm 4
Feb 13, 2025Whitlow Ricci SChief Operating OfficerSale61,420$8.28$508.6KForm 4
Mar 13, 2024Hulse William Frank IVGeneral Counsel and CAOSale20,381$7.95$162.0KForm 4
Feb 20, 2024Whitlow Ricci SChief Operating OfficerSale15,271$8.01$122.3KForm 4
Feb 16, 2024Whitlow Ricci SChief Operating OfficerSale15,493$8.07$125.0KForm 4
Feb 15, 2024Whitlow Ricci SChief Operating OfficerSale15,198$8.06$122.5KForm 4
Feb 14, 2024Whitlow Ricci SChief Operating OfficerSale15,845$8.03$127.2KForm 4
Nov 21, 2023DOUG RICEChief Financial OfficerBuy5,000$7.16$35.8KForm 4
Jun 23, 2023Capper Joseph HChief Executive OfficerBuy42,025$6.50$273.2KForm 4
Jun 22, 2023Capper Joseph HChief Executive OfficerBuy57,975$6.33$367.0KForm 4
May 16, 2023Stein Robert BenjaminPresident, Regenerative Med.Sale10,365$5.95$61.7KForm 4
May 15, 2023Stein Robert BenjaminPresident, Regenerative Med.Sale3,607$6.15$22.2KForm 4
May 10, 2023Hulse William Frank IVGeneral Counsel and CAOSale5,870$5.93$34.8KForm 4
May 10, 2023Stein Robert BenjaminPresident, Regenerative Med.Sale5,869$5.93$34.8KForm 4

All 62 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Essex Woodlands Management, Inc.28,195,249$108.6M42.7%No change
BlackRock, Inc.12,154,466$46.8M0.0%+243,166
Nantahala Capital Management, LLC9,535,104$36.7M1.1%+6,137,805
Trigran Investments, Inc.7,173,770$27.6M5.1%−1,339
State Street Corp5,578,920$21.5M0.0%+522,119
Vanguard Capital Management LLC5,187,053$20.0M0.0%+21,047
Paradigm Capital Management Inc/ny4,073,100$15.7M0.4%+662,800
Geode Capital Management, LLC3,143,488$12.1M0.0%+262,329
Goldman Sachs Group Inc2,665,562$10.3M0.0%+1,480,001
Aqr Capital Management LLC2,467,005$9.5M0.0%+1,554,277
Renaissance Technologies LLC2,444,230$9.4M0.0%−575,641
Punch & Associates Investment Management, Inc.2,058,089$7.9M0.4%+38,371
Dimensional Fund Advisors LP1,944,852$7.5M0.0%−749,150
Cannell Capital LLC1,870,436$7.2M5.0%+373,250
Northern Trust Corp1,317,575$5.1M0.0%+294,469
Vanguard Portfolio Management LLC1,290,476$5.0M0.0%+184,758
Arrowstreet Capital, Limited Partnership1,266,571$4.9M0.0%+490,730
Charles Schwab Investment Management Inc1,241,916$4.8M0.0%−137,249
Meros Investment Management, LP1,121,929$4.3M1.4%+28,901
Morgan Stanley1,043,286$4.0M0.0%+230,544
Qube Research & Technologies Ltd990,228$3.8M0.0%−661,291
Citadel Advisors LLC825,838$3.2M0.0%+49,397
Jane Street Group, LLC792,311$3.1M0.0%+266,839
Vanguard Fiduciary Trust Co775,085$3.0M0.0%−47,884
Kennedy Capital Management LLC770,075$3.0M0.1%New

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How MIMEDX GROUP, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARMIMEDX GROUP, INC.1
  • CIK0001376339
  • Employer ID (EIN)26-27925524
  • Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company4
  • Incorporated inFlorida4
  • Fiscal year endsDecember 311
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address1775 W Oak Commons Court, Ne, Marietta, GA 300621
  • Phone(770) 651-91001
  • Shares outstanding145,760,468 as of Jul 23, 202611
  • Public float$719.0M as of Jun 30, 20254
  • AuditorDeloitte & Touche LLP, Atlanta, Georgia PCAOB ID 34; it also attests to the company’s internal control over financial reporting4
  • On EDGAR sinceMar 6, 20071
  • Filings1,274 in all: 4 (495), 8-K (265), DEFA14A (78), 3 (57), 10-Q (52), DFAN14A (27), UPLOAD (24), 144 (22)1
    All 52 form types

    SC 13G/A (20), 5 (19), 10-K (17), SC 13D/A (16), SC 13G (16), DEF 14A (15), 8-K/A (14), CORRESP (12), S-8 (11), 10-K/A (9), SC 13D (9), NT 10-Q (8), PRE 14A (8), 4/A (7), 425 (7), 3/A (6), DEFC14A (5), PREC14A (5), CT ORDER (4), D (4), 10QSB (3), ARS (3), EFFECT (3), NT 10-K (3), PRRN14A (3), REGDEX (3), 424B5 (2), 8-A12B (2), DEFR14A (2), DFRN14A (2), PRER14A (2), S-3 (2), 10-KT (1), 10KSB (1), 10SB12G (1), 25-NSE (1), 424B3 (1), 8-A12B/A (1), 8-A12G (1), CERT (1), CERTNAS (1), S-4 (1), SC 14F1 (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (10-K) Feb 25, 2026
    Quarterly report (10-Q) Jul 29, 2026
    Proxy statement (DEF 14A) Apr 29, 2026
    Latest 8-K (8-K) Jul 29, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.001 per shareMDXGThe Nasdaq Stock Market LLC

From the cover page of the 10-K filed Feb 25, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks MIMEDX GROUP, INC. names in Item 1A of its 10-K filed Feb 25, 2026: 42 risks under these headings, as written.4

  • Risks Related to Our Business and Industry
  • If we do not successfully execute our priorities, our business, operating results and financial condition could be adversely affected.
  • We are in a highly competitive and evolving field and face competition from well-established tissue processors and medical device manufacturers, as well as new market entrants.
  • Rapid technological change could cause our products to become obsolete and, if we do not enhance our product offerings through our research and development efforts or business development and inorganic activities, we may be unable to compete effectively.
  • Many of our products depend on the availability of tissue from human donors, and any disruption in supply could adversely affect our business.
  • We depend on our senior leadership team and key employees and may not be able to retain or replace these employees or recruit additional qualified personnel, which would harm our business, results of operations and financial condition.
  • Our revenues depend on adequate reimbursement from public and private insurers and health systems and changes to the ways in which our products are reimbursed in various sites of service could adversely impact our financial results.
  • Our revenue, results of operations and cash flows may suffer upon the loss of a Group Purchasing Organization or Integrated Delivery Network.
  • We contract with and are dependent upon independent sales agents and distributors.
  • Disruption of our processing facilities could adversely affect our business, financial condition and results of operations.
  • To be commercially successful, we must educate physicians, where appropriate, how and when our products are proper alternatives to existing treatments and that our products should be used in their procedures.
  • If we cannot successfully address quality issues that may arise with our products, our brand reputation could suffer, and our business, financial condition, and results of operations could be adversely impacted.
The other 31 risks
  • The formation of physician-owned distributorships (“PODs”) could result in increased pricing pressure on our products or harm our ability to sell our products to physicians who own or are affiliated with those distributorships.
  • We face the risk of product liability claims and may not be able to obtain or maintain adequate product liability insurance.
  • The products we offer are derived from human and animal tissue and therefore have the potential for disease transmission.
  • We may implement a product recall or voluntary market withdrawal, which could significantly increase our costs, damage our reputation, disrupt our business and adversely affect our business, results of operations and financial condition.
  • A cyberattack or significant disruptions of our information technology systems could adversely affect our business, results of operation and financial condition.
  • Increased use of artificial intelligence (“AI”) and related technologies in the medical device industry could subject us to new risks and uncertainties, and our failure to effectively evaluate or adopt such technologies could adversely affect our business.
  • We may expand or contract our business through acquisitions, divestitures, licenses, investments, and other commercial arrangements with other companies or technologies, which may adversely affect our business, results of operations and financial condition.
  • A portion of our revenues and accounts receivable come from government accounts.
  • New lines of business or new products and services may subject us to additional risks.
  • Our international expansion and operations outside the U.S. expose us to risks associated with international sales and operations.
  • Risks Related to Regulatory Approval of Our Products and Other Government Regulations
  • The FDA has in the past determined, and may in the future determine, that certain of our products that are, or are derived from, human cells or tissues, do not qualify for regulation solely under Section 361, and may require that we revise our labeling and marketing claims for these products or that we suspend sales of such products until FDA pre-market clearance or approval is obtained, which could adversely affect our business, results of operations, and financial condition.
  • Obtaining and maintaining the necessary regulatory approvals, including conducting clinical trials, for certain of our products or potential products could be expensive and time consuming.
  • We may be subject to fines, penalties, injunctions and other sanctions if we are deemed to be promoting the use of our products for unapproved, or off-label, uses.
  • We and our sales representatives, whether employees or independent contractors, must comply with various federal and state anti-kickback, self-referral, false claims and similar laws, any breach of which could cause an adverse effect on our business, results of operations and financial condition.
  • Our results of operations may be adversely affected by current and potential future healthcare reforms.
  • We may fail to obtain or maintain foreign regulatory approvals to market our products in other countries.
  • Federal and state laws that protect the privacy and security of personal information may increase our costs and limit our ability to collect and use that information and subject us to liability if we are unable to fully comply with such laws.
  • Risks Related to Our Intellectual Property
  • Our ability to protect our intellectual property and proprietary technology through patents and other means is uncertain and may be inadequate, which could have an adverse effect on our business, results of operations and financial condition.
  • We may become subject to claims of infringement of the intellectual property rights of others, which could prohibit us from developing our products, require us to obtain licenses from third parties or to develop non-infringing alternatives, and subject us to substantial monetary damages.
  • We may be subject to damages resulting from claims that we, our employees, or our independent contractors have wrongfully used or disclosed alleged trade secrets, proprietary or confidential information of our competitors or are in breach of non-competition or non-solicitation agreements with our competitors.
  • Risks Related to Our Consolidated Financial Statements, Internal Controls and Related Matters
  • If we fail to maintain adequate internal control over financial reporting in the future, this could adversely affect our business, financial condition and operating results.
  • Risks Related to the Securities Markets and Ownership of Our Common Stock
  • Our indebtedness may adversely affect our financial health.
  • The restrictive covenants in the Citizens Credit Agreement, and the Company’s obligation to make payments under the Citizens Credit Agreement, limit our operating and financial flexibility and may adversely affect our business, results of operations and financial condition.
  • EW Healthcare Partners and its interests may conflict with those of our other shareholders.
  • The price of our Common Stock has been, and will likely continue to be, volatile.
  • Securities analysts may elect not to report on our common stock or may issue negative reports that adversely affect the stock price.
  • Fluctuations in revenue or results of operations could cause additional volatility in our stock price.
  • We do not intend to pay cash dividends on our Common Stock.
  • Our capital allocation decisions, including decisions regarding share repurchases, investments in inorganic opportunities, and other capital allocation activities, may not achieve their intended benefits and could adversely affect our financial condition and stock price.
  • Certain provisions of Florida law and anti-takeover provisions in our organizational documents may discourage or prevent a change of control, even if an acquisition would be beneficial to shareholders, which could affect our share price adversely and prevent attempts by shareholders to remove current management.

Legal proceedings

The description of the Company’s legal proceedings contained in Note 14, Commitments and Contingencies to our financial statements included in Item 8 is incorporated herein by reference.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86